Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 13/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6518308 | 0.99 | HTR6 (0.44) | PKMMEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL4304442 | 0.90 | HTR6 (0.54) | PKMHTR6CA12CA2CA9 | |
| Hydrochloric Acid SCHEMBL6521806 | 0.89 | HTR6 (0.53) | PKMHTR6CA12CA2CA9 | |
| Hydrochloric Acid SCHEMBL4316251 | 0.89 | HTR6 (0.53) | PKMHTR6CA12CA2CA9 | |
| SCHEMBL17422147 | 0.88 | ALOX5 (0.52) | PKMHTTHTR6LMNAALOX5 | |
| SCHEMBL4316005 | 0.88 | MAPT (0.51) | PKMHTTL3MBTL1HTR6MAPT | |
| Hydrochloric Acid SCHEMBL6518351 | 0.87 | HTR6 (0.50) | PKMHTTHTR6MAPT | |
| SCHEMBL4317729 | 0.86 | HTR6 (0.45) | PKML3MBTL1HTR6CA12CA2 | |
| Hydrochloric Acid SCHEMBL6519613 | 0.85 | HTR6 (0.44) | PKML3MBTL1HTR6CA12CA2 | |
| SCHEMBL4312512 | 0.85 | NOD1 (0.50) | PKMKMT2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524839-B2 | Compounds, their use and preparation | BIOVITRUM AM (PUBL.) | 2009-04-28 | — | — | US | claimed |
| US-7524839-B2 | Compounds, their use and preparation | BIOVITRUM AM (PUBL.) | 2009-04-28 | — | — | US | disclosed |
| CN-101298433-A | 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy | BIOVITRUM AB (SE) | 2008-11-05 | — | — | CN | disclosed |
| CN-100378074-C | 2-, 3-, 4-or 5-substituted N1- (phenylsulfonyl) indoles and their therapeutic use | BIOVITRUM AB (SE) | 2008-04-02 | — | — | CN | disclosed |
| US-7087750-B2 | Compounds, their use and preparation | BIOVITRUM AB (SE) | 2006-08-08 | — | — | US | disclosed |
| CN-1714077-A | 2-, 3-, 4-or 5-substituted N1- (phenylsulfonyl) indoles and their therapeutic use | BIOVITRUM AB (SE) | 2005-12-28 | — | — | CN | disclosed |
| US-20050256106-A1 | Novel compounds, their use and preparation | BIOVITRUM AB, A STOCKHOLM, SWEDEN CORPORATION | 2005-11-17 | — | — | US | disclosed |
| US-20020165251-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165251-A1 | Novel compounds, their use and preparation | HTR6, HTR1A, HTR5A | PKM 3560/4885MEN1 2265/4885HTT 465/4885 |
| US-20050256106-A1 | Novel compounds, their use and preparation | HTR6, HTR3C, HTR1A | PKM 3206/4885MEN1 2008/4885HTT 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.